Cytek Biosciences Q2 2026 revenue $48.1M (+6% YoY); net loss widens to $12.2M from $5.6M

Cytek Biosciences, Inc.

Total revenue $48.1M, up 6% YoY; GAAP gross margin improved to 59% from 52%.
Net loss $12.2M vs $5.6M loss YoY; adjusted EBITDA loss $1.5M vs positive $1.3M.
Operating expenses rose 15% to $39.7M, driven by litigation, severance, and personnel costs.
Full-year 2026 revenue guidance raised to $207M-$212M, midpoint up $1M.
Launched Cytek Borealis 7-laser, 60-color cytometer; installed base reached 3,933 units.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.